Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, outlines treatment options for patients with high-risk myelofibrosis (MF) ineligible for allogeneic stem cell transplantation (alloSCT). Whilst the two currently approved JAK inhibitors in Europe, ruxolitinib and fedratinib are useful to manage constitutional symptoms and splenomegaly, they are also associated with cytopenia. Two recently developed JAK inhibitors, momelotinib and pacritinib, help improve both anemia and symptoms, and their approval in Europe is eagerly awaited. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
